JP2011503547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503547A5 JP2011503547A5 JP2010532284A JP2010532284A JP2011503547A5 JP 2011503547 A5 JP2011503547 A5 JP 2011503547A5 JP 2010532284 A JP2010532284 A JP 2010532284A JP 2010532284 A JP2010532284 A JP 2010532284A JP 2011503547 A5 JP2011503547 A5 JP 2011503547A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- biomarkers
- subject
- steatohepatitis
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 34
- 239000000523 sample Substances 0.000 claims 28
- 208000004930 Fatty Liver Diseases 0.000 claims 26
- 238000000034 method Methods 0.000 claims 17
- 239000012472 biological sample Substances 0.000 claims 14
- 238000000338 in vitro Methods 0.000 claims 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 210000002700 urine Anatomy 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 2
- 238000005842 biochemical reaction Methods 0.000 claims 2
- 238000006911 enzymatic reaction Methods 0.000 claims 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- NKAGVXWBYVCPRT-UHFFFAOYSA-N 3-hydroxy-3-[(trimethylazaniumyl)methyl]hex-4-ynoate Chemical compound C(#CC)C(O)(C[N+](C)(C)C)CC([O-])=O NKAGVXWBYVCPRT-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- SITLTJHOQZFJGG-XPUUQOCRSA-N Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SITLTJHOQZFJGG-XPUUQOCRSA-N 0.000 claims 1
- 108010007979 Glycocholic Acid Proteins 0.000 claims 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 claims 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- 229940099352 cholate Drugs 0.000 claims 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- MYFMARDICOWMQP-YUMQZZPRSA-N gamma-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CC[C@H](N)C(O)=O MYFMARDICOWMQP-YUMQZZPRSA-N 0.000 claims 1
- XHHOHZPNYFQJKL-QWRGUYRKSA-N gamma-Glu-Phe Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XHHOHZPNYFQJKL-QWRGUYRKSA-N 0.000 claims 1
- VVLXCWVSSLFQDS-QWRGUYRKSA-N gamma-Glu-Tyr Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VVLXCWVSSLFQDS-QWRGUYRKSA-N 0.000 claims 1
- 108010064169 gamma-glutamyl-leucine Proteins 0.000 claims 1
- 108010030535 gamma-glutamylphenylalanine Proteins 0.000 claims 1
- 108010089460 gamma-glutamyltyrosine Proteins 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- -1 metabolite-11728 Chemical compound 0.000 claims 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 claims 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98494207P | 2007-11-02 | 2007-11-02 | |
| US60/984,942 | 2007-11-02 | ||
| US4245908P | 2008-04-04 | 2008-04-04 | |
| US61/042,459 | 2008-04-04 | ||
| PCT/US2008/082013 WO2009059150A2 (en) | 2007-11-02 | 2008-10-31 | Biomarkers for fatty liver disease and methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503547A JP2011503547A (ja) | 2011-01-27 |
| JP2011503547A5 true JP2011503547A5 (cg-RX-API-DMAC7.html) | 2011-12-08 |
| JP5270684B2 JP5270684B2 (ja) | 2013-08-21 |
Family
ID=40591773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532284A Active JP5270684B2 (ja) | 2007-11-02 | 2008-10-31 | 脂肪肝疾患用のバイオマーカー及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20100279956A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2546649B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5270684B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2402142T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009059150A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009001862A1 (ja) * | 2007-06-25 | 2008-12-31 | Ajinomoto Co., Inc. | 内臓脂肪蓄積の評価方法 |
| EP2546649B1 (en) * | 2007-11-02 | 2015-02-25 | Metabolon Inc. | Biomarkers for fatty liver disease and methods using the same |
| WO2009153136A2 (en) | 2008-05-28 | 2009-12-23 | Basf Se | Means and methods for assessing liver toxicity |
| WO2009153131A1 (en) * | 2008-05-28 | 2009-12-23 | Basf Se | Means and methods for assessing liver enzyme induction |
| CN102265160B (zh) * | 2008-12-24 | 2014-07-23 | 学校法人庆应义塾 | 肝病标记物、其测定方法、装置和医药品的检验方法 |
| WO2011029899A1 (en) * | 2009-09-11 | 2011-03-17 | The Chinese University Of Hong Kong | Methods for assessing liver pathologies |
| JP2011232164A (ja) * | 2010-04-27 | 2011-11-17 | Keio Gijuku | 肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法 |
| EP2863227B1 (en) * | 2010-06-10 | 2017-09-27 | Metanomics Health GmbH | Means and methods for metabolic differentiation of non-alcoholic steatohepatitis from liver disease |
| US20130116148A1 (en) * | 2010-06-18 | 2013-05-09 | Keio University | Liver disease marker, method and apparatus for measuring the same, and method for assaying pharmaceutical preparation |
| US8728824B2 (en) | 2011-06-22 | 2014-05-20 | Quest Diagnostics Investments Inc. | Mass spectrometric determination of fatty acids |
| WO2013002381A1 (ja) * | 2011-06-30 | 2013-01-03 | 味の素株式会社 | 脂肪性肝疾患の評価方法、脂肪性肝疾患評価装置、脂肪性肝疾患評価方法、脂肪性肝疾患評価プログラム、脂肪性肝疾患評価システム、情報通信端末装置、および脂肪性肝疾患の予防・改善物質の探索方法 |
| BR112015006284A2 (pt) | 2012-09-21 | 2017-07-04 | Governing Council Univ Toronto | cpmf como um biomarcador para diabetes e métodos associados |
| WO2016049828A1 (zh) * | 2014-09-30 | 2016-04-07 | 深圳华大基因科技有限公司 | 肥胖人群特异性生物标志组合物及其用途 |
| EP3221463A4 (en) * | 2014-11-19 | 2018-07-25 | Metabolon, Inc. | Biomarkers for fatty liver disease and methods using the same |
| RU2617236C1 (ru) * | 2015-12-02 | 2017-04-24 | государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации | Способ определения целесообразности проведения иммунологического обследования у пациентов неалкогольной жировой болезнью печени |
| US12285464B2 (en) | 2016-04-18 | 2025-04-29 | The Trustees Of Columbia University In The City Of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (NASH) |
| CN115236166A (zh) | 2016-05-29 | 2022-10-25 | 深圳市绘云生物科技有限公司 | 肝病相关生物标志物和其使用方法 |
| EP3502703A1 (en) | 2017-12-22 | 2019-06-26 | Metanomics Health GmbH | Method for the assessment of nafld |
| CN109060977B (zh) * | 2018-07-13 | 2024-07-02 | 深圳市绘云生物科技有限公司 | 用于肝纤维化和肝硬化诊断的生物标志物和试剂盒及使用方法 |
| US11693005B2 (en) | 2018-08-07 | 2023-07-04 | Florida Atlantic University Board Of Trustees | Methods for identifying treatments that reduce the actions of substances of abuse and addiction |
| JP6998023B2 (ja) * | 2018-09-26 | 2022-02-10 | 株式会社島津製作所 | 非アルコール性脂肪肝疾患の検出方法、非アルコール性脂肪肝疾患検出用キットおよび非アルコール性脂肪肝疾患検出用バイオマーカー |
| WO2020154567A1 (en) * | 2019-01-25 | 2020-07-30 | Viscient Biosciences, Inc. | Compositions and methods for the diagnosis and treatment of diseases of the liver |
| US20230203583A1 (en) * | 2020-05-04 | 2023-06-29 | University Of Florida Research Foundation, Incorporated | Biomarkers for assessing liver disease |
| US20230137741A1 (en) | 2021-11-01 | 2023-05-04 | Matterworks Inc | Methods and compositions for analyte quantification |
| US12100484B2 (en) | 2021-11-01 | 2024-09-24 | Matterworks Inc | Methods and compositions for analyte quantification |
| CN116165385B (zh) * | 2023-04-25 | 2023-07-18 | 南方医科大学南方医院 | 用于肝癌诊断的血清代谢标志物及其筛选方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61260896A (ja) * | 1985-05-15 | 1986-11-19 | Sekisui Chem Co Ltd | 胆汁酸の分析方法 |
| WO1996037777A1 (en) * | 1995-05-23 | 1996-11-28 | Nelson Randall W | Mass spectrometric immunoassay |
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| EP1285092A4 (en) | 2000-04-14 | 2003-07-16 | Metabolon Inc | METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS |
| WO2002092768A2 (en) * | 2001-05-14 | 2002-11-21 | University Of Maryland, Baltimore | Novel alanine transaminase enzyme and methods of use |
| JP2003139753A (ja) * | 2001-11-02 | 2003-05-14 | Mitsubishi Pharma Corp | 胆汁酸１８成分の一斉分析法 |
| US20040121305A1 (en) * | 2002-12-18 | 2004-06-24 | Wiegand Roger Charles | Generation of efficacy, toxicity and disease signatures and methods of use thereof |
| ES2226549B1 (es) * | 2002-12-18 | 2006-07-16 | One Way Liver Genomics, S.L. | Metodo para el diagnostico de esteatohepatitis no alcoholica (nash) mediante el empleo de marcadores moleculares. |
| US7452678B2 (en) * | 2003-06-24 | 2008-11-18 | Bristol-Myers Squibb Company | Identification of biomarkers for liver toxicity |
| CA2546601A1 (en) * | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| US7078064B2 (en) * | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| EP1739431A4 (en) * | 2004-04-23 | 2008-10-15 | Ajinomoto Kk | METHOD FOR ASSESSING NON-ALCOHOLIC STEATOHEPATITIS |
| EP1619257A1 (en) * | 2004-07-23 | 2006-01-25 | One Way Liver Genomics, S.L. | Method for the in vitro diagnosis of non-alcoholic steatohepatitis |
| US20060160237A1 (en) * | 2004-12-06 | 2006-07-20 | Applera Corporation | Method of screening urine for organic acids |
| US7860656B2 (en) * | 2005-02-03 | 2010-12-28 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of hepatic steatosis using biochemical markers |
| US20070004045A1 (en) * | 2005-06-07 | 2007-01-04 | Xia Xu | Analysis of large numbers of estrogens and other steroids and applications thereof |
| US7972785B2 (en) * | 2006-01-24 | 2011-07-05 | Industrial Technology Research Institute (Itri) | Biomarkers for liver fibrotic injury |
| JP5227168B2 (ja) * | 2006-03-29 | 2013-07-03 | ヤマサ醤油株式会社 | 肝障害の検出方法、判定方法及び予測方法 |
| EP2009444B1 (en) * | 2006-04-06 | 2012-02-29 | Eisai R&D Management Co., Ltd. | Non-invasive test method for non-alcoholic steatohepatitis based on cytochrome-c quantification |
| WO2007136674A1 (en) | 2006-05-19 | 2007-11-29 | The Cleveland Clinic Foundation | Detection and monitoring of liver damage |
| ES2527438T3 (es) * | 2006-08-08 | 2015-01-26 | Metabolon, Inc. | Marcadores de la hepatopatía grasa no alcohólica (NAFLD) y de la esteatohepatitis no alcohólica (NASH) y métodos de uso de los mismos |
| US20090075284A1 (en) * | 2006-09-19 | 2009-03-19 | The Regents Of The University Of Michigan | Metabolomic profiling of prostate cancer |
| WO2008056480A1 (en) * | 2006-11-06 | 2008-05-15 | Yokohama City University | Diagnosis method for fatty liver disease, diagnosis apparatus, diagnosis program, diagnostic agent, and method for screening for therapeutic agent for fatty liver disease |
| WO2008156662A1 (en) * | 2007-06-14 | 2008-12-24 | George Mason Intellectual Properties, Inc. | Methods of diagnosing non-alcoholic steatohepatitis (nash) |
| BRPI0815095B1 (pt) * | 2007-07-17 | 2021-04-13 | Metabolon, Inc | Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo |
| EP2546649B1 (en) * | 2007-11-02 | 2015-02-25 | Metabolon Inc. | Biomarkers for fatty liver disease and methods using the same |
| WO2010045180A1 (en) * | 2008-10-13 | 2010-04-22 | Metabolon, Inc. | Biomarkers for inflammatory bowel disease and methods using the same |
-
2008
- 2008-10-31 EP EP12188223.7A patent/EP2546649B1/en active Active
- 2008-10-31 EP EP15155591.9A patent/EP2930512B1/en active Active
- 2008-10-31 ES ES08845659T patent/ES2402142T3/es active Active
- 2008-10-31 JP JP2010532284A patent/JP5270684B2/ja active Active
- 2008-10-31 EP EP08845659A patent/EP2227689B1/en active Active
- 2008-10-31 WO PCT/US2008/082013 patent/WO2009059150A2/en not_active Ceased
-
2010
- 2010-04-30 US US12/771,729 patent/US20100279956A1/en not_active Abandoned
-
2015
- 2015-09-02 US US14/843,356 patent/US9977034B2/en active Active
-
2018
- 2018-04-18 US US15/955,883 patent/US20190120855A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503547A5 (cg-RX-API-DMAC7.html) | ||
| Chen et al. | Unilateral ureteral obstruction causes gut microbial dysbiosis and metabolome disorders contributing to tubulointerstitial fibrosis | |
| Petriz et al. | Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats | |
| Risch et al. | The serum uromodulin level is associated with kidney function | |
| WO2010083252A3 (en) | Ratio based biomarkers and methods of use thereof | |
| JP2018502286A5 (cg-RX-API-DMAC7.html) | ||
| WO2008036835A3 (en) | Methods and compositions for upregulation of peroxiredoxin activity | |
| JP2012526554A5 (cg-RX-API-DMAC7.html) | ||
| WO2006026020A3 (en) | Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin | |
| WO2014170497A3 (en) | Method for identifying the quantitative cellular composition in a biological sample | |
| HK1199754A1 (en) | Method for monitoring, diagnosis and/or prognosis of acute kidney injury in early stage | |
| WO2008008515A3 (en) | Methods and compositions for detecting rare cells from a biological sample | |
| ATE452343T1 (de) | Verbesserte vitamin-d-messung | |
| WO2011133668A3 (en) | Methods and compositions for the treatment of cancer | |
| BR112012019542A2 (pt) | "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit" | |
| JP2016520192A5 (cg-RX-API-DMAC7.html) | ||
| WO2007018843A3 (en) | Methods and compositions for diagnosis and treatment of influenza | |
| US10724097B2 (en) | Methods and compositions for diagnosis and management of diabetes and metabolic syndrome | |
| BRPI0717633A2 (pt) | Anticorpo, composição farmacêutica, e, métodos para detectar uma célula expressando cxcr7 em uma amostra biológica, para tratar, prevenir ou melhorar uma doença e para identificar um modulador de cxcr7 | |
| BR112012031045A2 (pt) | métodos para detecção de uma condição, para determinar a eficácia de um tratmento terapêutico de uma condição, e para a seleção de um sujeito que sofre de uma condição, e, kit. | |
| WO2007124309A3 (en) | Methods for detecting mutations in jak2 nucleic acid | |
| WO2009043848A3 (en) | Use of the serological assay of the cytokine b-lymphocyte stimulator (blys) for the diagnosis, prognosis and the screening of therapeutic efficacy in immune-related diseases including organ-specific autoimmune diseases and transfusion reactions | |
| Cherian et al. | Increased circulation and adipose tissue levels of DNAJC27/RBJ in obesity and type 2-diabetes | |
| CN103814295A (zh) | 用于评估肾毒性的手段和方法 | |
| WO2008067008A3 (en) | A method for the quantitative evaluation of sex hormones in a serum sample |